Luminex Corporation has received FDA clearance for the MAGPIX instrument, with its xTAG Gastrointestinal Pathogen Panel (xTAG GPP). The first clinical assay to be cleared on MAGPIX simultaneously detects 11 common viral, bacterial, and parasitic causes of infectious gastroenteritis from a single patient sample. Company spokespersons say this multiplexing instrument enables simultaneous testing for more than 90% of bacterial, viral, and parasitic causes of infectious gastroenteritis in one molecular test.
Based on Luminex's xMAP Technology, the MAGPIX instrument is a multiplexing platform capable of performing qualitative and quantitative analysis of proteins and nucleic acids in a variety of sample matrices. The system can perform up to 50 different tests in a single reaction volume, greatly reducing sample input, reagents, and labor while improving productivity.
Traditional GI testing technologies and methods, Luminex representatives note, can take several days to deliver a single result depending on the pathogen; xTAG GPP can deliver multiple results within five hours. Simultaneous molecular testing on a single sample within a single shift provides significant benefits to laboratories in terms of workflow and resource utilization.
Luminex will be featuring xTAG GPP and demonstrating the MAGPIX instrument at the Clinical Virology Symposium (CVS), April 28–May 1 in Daytona Beach, FL, Booth #237. Learn more about Luminex assays.
